Robert W Duggan bought $500k of SMMT
Co-Chief Executive Officer at Summit Therapeutics Inc.. 26,680 shares at an average of $18.74, traded Oct 21, 2025, filed Oct 23, 2025.
Score components
- +25RoleCEO
- +18Trade size$500k at market
- +10Relative to holdingsHoldings up 53%
- 0Price contextNo price history yet
- +15Cluster3 insiders buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -13.7%, 3m -7.4%, 6m +18.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001055919-25-000003, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 21, 2025 | AGrant or award Common Stock | +13,980,789 | $18.74 | $262M | 570,073,879 | Oct 23, 2025 |
| Oct 21, 2025 | AGrant or award Common Stockindirect: By the Mahkam Zanganeh Revocable Trust, with the Spouse of Reporting Person as Trustee | +266,808 | $18.74 | $5.0M | 25,724,474 | Oct 23, 2025 |
| Oct 21, 2025 | POpen-market purchase Common Stockindirect: Immediate family member of Spouse | +26,680 | $18.74 | $500k | 76,680 | Oct 23, 2025 |
Related signals
Other insiders at Summit Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 78Notable | Summit Therapeutics Inc. | Robert W Duggan Co-Chief Executive Officer | $50M 3,810,000 shares | +1% | |
| 83Strong | Summit Therapeutics Inc. | Mahkam Zanganeh Co-Chief Executive Officer | $50M 3,810,000 shares | +1% | |
| 73Notable | Summit Therapeutics Inc. | Robert W Duggan Co-Chief Executive Officer | $1.5M 100,000 shares | +0% | |
| 76Notable | Summit Therapeutics Inc. | Manmeet Singh Soni COO and CFO | $722k 50,000 shares | +2% | |
| 78Notable | Summit Therapeutics Inc. | Mahkam Zanganeh Co-Chief Executive Officer | $1.5M 100,000 shares | +0% | |
| 73Notable | Summit Therapeutics Inc. | Mahkam Zanganeh Co-Chief Executive Officer | $500k 26,680 shares | +53% | |
| 55Moderate | Summit Therapeutics Inc. | Yu Xia director | $10.0M 533,617 shares | +2% | |
| 53Moderate | Summit Therapeutics Inc. | Robert W Duggan Co-Chief Executive Officer | $6.0M 338,394 shares | +0% | |
| 53Moderate | Summit Therapeutics Inc. | Mahkam Zanganeh Co-Chief Executive Officer | $6.0M 338,394 shares | +0% | |
| 56Moderate | Summit Therapeutics Inc. | Ankur Dhingra Chief Financial Officer | $375k 100,000 shares | +39% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.